Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 6/20 | 0.40 |
| ▸ | KDM5A | P29375 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1653319 | 0.91 | KIT (0.46) | HTR2BPDK2AOC3KDM5AROCK2 | |
| SCHEMBL10069537 | 0.89 | HSD11B1 (0.43) | HSD11B1KDM5AHRH3TLR9TLR8 | |
| SCHEMBL10070119 | 0.88 | LIPE (0.47) | PDK2AOC3TRPA1FAAH | |
| SCHEMBL10070093 | 0.86 | CPT1A (0.40) | AOC3KDM5AROCK2ROCK1TLR9 | |
| SCHEMBL10069712 | 0.84 | CPT1A (0.48) | HSD11B1KDM5ATLR9TLR8TLR7 | |
| SCHEMBL10070552 | 0.83 | HTR2B (0.43) | HTR2BHSD11B1KDM5AHRH3TLR9 | |
| SCHEMBL10069541 | 0.82 | AKT1 (0.39) | AOC3KDM5AFAAH | |
| SCHEMBL10070100 | 0.82 | CPT2 (0.49) | P2RY12TRPA1 | |
| SCHEMBL10070551 | 0.80 | AOC3 (0.45) | PDK2AOC3KDM5AFAAH | |
| SCHEMBL1653375 | 0.79 | CNR1 (0.53) | PDK2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308869-B1 | AZOLE COMPOUND | ASTELLAS PHARMA INC (JP) | 2012-09-19 | — | — | EP | disclosed |
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2308869-A1 | AZOLE COMPOUND | Astellas Pharma Inc. (JP) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010007966-A1 | AZOLE COMPOUND | アステラス製薬株式会社 (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118311-A1 | AZOLE COMPOUND | FAAH, FAAH2, TRPV1 | HTR2B 2418/4885HSD11B1 2752/4885PDK2 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.